Northwest Biotherapeutics (NWBO) EBT Margin (2010 - 2026)

Northwest Biotherapeutics' EBT Margin history runs 17 years deep, the most recent figure standing at 2681.38% for Q1 2026.

• On a quarterly basis, EBT Margin rose 236209.0% year-over-year to 2681.38% in Q1 2026; TTM through Mar 2026 was 4747.03%, a 76479.0% increase from a year earlier, with the FY2025 full-year figure at 4404.86%, up 165722.0% from the prior year.
• EBT Margin slipped to 2681.38% in Q1 2026 per NWBO's latest filing, from 2399.7% in the prior quarter.
• Across five years, EBT Margin topped out at 1589.89% in Q1 2023 and bottomed at 63220.87% in Q3 2022.
• The 5-year median for EBT Margin is 4723.48% (2022), against an average of 9037.69%.
• Across the five-year window, EBT Margin slumped 5989145 bps in 2022 and surged 5939698 bps in 2023, its largest moves.
• Year by year, EBT Margin stood at 3257.29% in 2022, then rose by 17 bps to 2693.93% in 2023, then plunged by 322 bps to 11355.41% in 2024, then surged by 79 bps to 2399.7% in 2025, then declined by 12 bps to 2681.38% in 2026.
• Per Business Quant, the three latest NWBO EBT Margin figures stand at 2681.38% (Q1 2026), 2399.7% (Q4 2025), and 8470.5% (Q3 2025).